Provided by Tiger Trade Technology Pte. Ltd.

Incyte

108.39
+5.635.48%
Post-market: 107.91-0.4800-0.44%19:47 EST
Volume:2.19M
Turnover:234.97M
Market Cap:21.28B
PE:18.36
High:108.52
Open:103.75
Low:103.52
Close:102.76
52wk High:112.29
52wk Low:53.56
Shares:196.32M
Float Shares:163.04M
Volume Ratio:1.21
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.90
EPS(LYR):0.1500
ROE:30.39%
ROA:13.54%
PB:4.58
PE(LYR):722.60

Loading ...

Earning Preview: Incyte Q4 revenue is expected to increase by 18.35%, and institutional views are broadly constructive

Earnings Agent
·
Feb 03

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 07

Incyte Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 07

Incyte price target raised to $110 from $102 at Piper Sandler

TIPRANKS
·
Feb 06

Incyte : Piper Sandler Raises Target Price to $110 From $102

THOMSON REUTERS
·
Feb 06

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

Benzinga_recent_news
·
Feb 06

Latest Ratings from Top Wall Street Analysts: Microsoft Downgraded, Snap Upgraded

Deep News
·
Feb 06

Barclays Adjusts Price Target on Incyte to $116 From $115, Maintains Overweight Rating

MT Newswires Live
·
Feb 06

Incyte Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 05

HC Wainwright Initiates Incyte at Buy With $135 Price Target

MT Newswires Live
·
Feb 05

Incyte Corporation : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $135

THOMSON REUTERS
·
Feb 05

Tafasitamab-Parsaclisib Trial Termination Tempers Incyte Outlook

TIPRANKS
·
Feb 05

Incyte Is Maintained at Overweight by Barclays

Dow Jones
·
Feb 04

Barclays Keeps Their Buy Rating on Incyte (INCY)

TIPRANKS
·
Feb 04

BUZZ-Prelude Therapeutics rises after FDA clears early-stage trial of blood cancer drug

Reuters
·
Feb 03

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 03

Incyte CHMP Win For Zynyz Adds Weight To Oncology Diversification Story

Simply Wall St.
·
Feb 01

Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Roche Holding AG (OtherRHHVF) and Incyte (INCY)

TIPRANKS
·
Jan 31

EMA Panel Recommends Approval of Incyte's Zynyz for Advanced Anal Cancer

Reuters
·
Jan 30

Incyte Announces Positive Chmp Opinion for Zynyz® (Retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (Scac)

THOMSON REUTERS
·
Jan 30